Tet2 restrains inflammatory gene expression in macrophages
Top Cited Papers
Open Access
- 18 August 2017
- journal article
- research article
- Published by Elsevier BV in Experimental Hematology
- Vol. 55, 56-70.e13
- https://doi.org/10.1016/j.exphem.2017.08.001
Abstract
No abstract availableKeywords
Funding Information
- Queen's University
- Canada Foundation for Innovation
- Ontario Institute for Cancer Research
- Southeastern Ontario Academic Medical Organization
- Women's Giving Circle/University Hospitals Kingston Foundation
- Queen's University Terry Fox Foundation Training Program in Transdisciplinary Cancer Research
This publication has 61 references indexed in Scilit:
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013
- Prognostic Score Including Gene Mutations in Chronic Myelomonocytic LeukemiaJournal of Clinical Oncology, 2013
- Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevanceLeukemia, 2011
- Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1Journal of Clinical Oncology, 2010
- Epigenetic Changes in the Myelodysplastic SyndromeHematology/Oncology Clinics of North America, 2010
- Acquired mutations in TET2 are common in myelodysplastic syndromesNature Genetics, 2009
- Mutation inTET2in Myeloid CancersNew England Journal of Medicine, 2009
- Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AMLLeukemia, 2009
- Epigenetic Changes in Solid and Hematopoietic TumorsSeminars in Oncology, 2005
- Epigenetic targets in hematopoietic malignanciesOncogene, 2003